Redmile Group, a hedge fund and private equity manager, and Bain Capital Life Sciences, a fund that specializes in buyouts, inflection capital, growth capital, turnaround, and private equity investments, led a $155m Series B funding round in Abcuro, a clinical-stage biotechnology company, with participation from RA Capital Management, Samsara BioCapital, Sanofi Ventures, New Leaf Ventures, Pontifax, Tekla Capital Management, LLC, BlackRock, Mass General Brigham Ventures, Eurofarma, and Soleus Capital. “Support from such a strong group of investors will allow us to complete our development programs in diseases where there are few to no treatment options available. We are very motivated by the patients we serve and are excited by the clinical data we’ve seen to date. We’re committed to executing on our clinical trials including our registrational trial in inclusion body myositis,” Alex Martin, Abcuro CEO.